ArticleGenome medicine2016
Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet.
Article in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 210 citations in OpenAlex.
- Pooled it
- From gut dysbiosis to eubiosis: understanding microbiome recovery as an ecological process.Gut microbes · 2026Review
- Early-life gut dysbiosis programs divergent metabolic trajectories in a sex-dependent manner.Gut microbes · 2026Article
- Antibiotic-induced gut microbiome dysbiosis: risks and strategies for mitigation.The EMBO journal · 2026Review
- Duration-dependent gut microbiota disruption drives opposing effects on adipose thermogenesis in obese mice.Frontiers in microbiology · 2026Article
- Pathogenesis and intervention strategies for metabolic dysfunction-associated fatty liver disease from the perspective of the gut-microbiota-liver axis.Frontiers in immunology · 2026Review
- Progressive microbial alterations in the human gut and lung across early life: implications for translational medicine.Frontiers in cellular and infection microbiology · 2026Review
- Antibiotic exposure alters the LEAP-2/ghrelin axis and anti-inflammatory tone in aged male rat liver and adipose tissue.Biogerontology · 2025Article
- [1]The human gut microbiota in IBD, characterizing hubs, the core microbiota and terminal nodes: a network-based approach.BMC microbiology · 2025Article
- Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer.Clinical and molecular hepatology · 2025Review
- Unveiling the Important Role of Gut Microbiota and Diet in Multiple Sclerosis.Brain sciences · 2025Review
- Integrating network analysis with in vivo-in situ manipulation to elucidate microbiome dynamics in Aedes albopictus.FEMS microbiology letters · 2025Article
- Invariant Natural Killer T lymphocytes as natural sensors for microbes: a two-edged sword in liver diseases.Frontiers in immunology · 2025Review
- A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis.Frontiers in microbiology · 2025Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.Frontiers in medicine · 2025Review
- Microbial community variations in adultFrontiers in microbiology · 2025Article
- Article
- Alzheimer's Disease Has Its Origins in Early Life via a Perturbed Microbiome.The Journal of infectious diseases · 2024Review
- Disruption of bacterial interactions and community assembly in Babesia-infected Haemaphysalis longicornis following antibiotic treatment.BMC microbiology · 2024Article
- The individual response to antibiotics and diet - insights into gut microbial resilience and host metabolism.Nature reviews. Endocrinology · 2024Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundObesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are serious health concerns, especially in Western populations. Antibiotic exposure and high-fat diet (HFD) are important and modifiable factors that may contribute to these diseases.
methodsTo investigate the relationship of antibiotic exposure with microbiome perturbations in a murine model of growth promotion, C57BL/6 mice received lifelong sub-therapeutic antibiotic treatment (STAT), or not (control), and were fed HFD starting at 13 weeks. To characterize microbiota changes caused by STAT, the V4 region of the 16S rRNA gene was examined from collected fecal samples and analyzed.
resultsIn this model, which included HFD, STAT mice developed increased weight and fat mass compared to controls. Although results in males and females were not identical, insulin resistance and NAFLD were more severe in the STAT mice. Fecal microbiota from STAT mice were distinct from controls. Compared with controls, STAT exposure led to early conserved diet-independent microbiota changes indicative of an immature microbial community. Key taxa were identified as STAT-specific and several were found to be predictive of disease. Inferred network models showed topological shifts concurrent with growth promotion and suggest the presence of keystone species.
conclusionsThese studies form the basis for new models of type 2 diabetes and NAFLD that involve microbiome perturbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.